Pantoprazole icd 10 code

Transcription

1 Pantoprazole icd 10 code in persons with recurrent or metastatic non-small cell lung cancer who are being considered for treatment with dabrafenib (Tafinlar), pembrolizumab (Keytruda), or vemurafenib (Zelboraf); or. Aetna considers testing for genetic polymorphisms of dihydropyrimidine dehydrogenase and thymidylate synthase to predict 5-fluorouracil toxicity experimental and investigational because the clinical value of such testing has not been established. Aetna considers UrSure tenofovir quantification test experimental and investigational for adherence monitoring to pre-exposure prophylaxis established. Aetna considers CYP2C19 polymorphisms testing for fluoxetine experimental and investigational. Aetna considers laboratory testing to allow area under the curve (AUC)-targeted 5- fluorouracil dosing (e.g., Myriad Genetics'

2 OnDose) experimental and investigational established. Aetna considers beta adrenergic receptor genotyping experimental and investigational for evaluating persons with treatment resistant asthma and for all other indications. CPB BRCA Testing, Prophylactic Mastectomy, and Prophylactic Oophorectomy,. Aetna considers detecting mutations of the BRAF gene (V600E or V600K) (e.g., the THxID BRAF test or the cobas 4800 BRAF mutation test) medically necessary for the following indications: Aetna considers an FDA-approved test for the anaplastic lymphoma kinase (ALK) fusion gene (e.g., the Vysis ALK Break Apart FISH Probe Kit; Ventana ALK (D5F3) CDx Assay) medically necessary for persons who are considering crizotinib (Xalkori) or ceritinib (Zykadia) for the treatment of non-small cell lung cancer (NSCLC). Aetna considers testing to detect an epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations (e.g., cobas EGFR Mutation Test, therascreen EGFR RGQ PCR Kit) medically necessary for persons with non-small cell lung cancer being considered for treatment with erlotinib (Tarceva) or afatinib (Gilotrif). Pharmacogenomics testing is laboratory testing which has the potential to determine how an individual's genetic factors may affect the safety and effectiveness of that individual's response to a specific medication. The goal of pharmacogenomics testing is to reduce the incidence of adverse medication reactions while improving an individual's positive response to the medication. Additionally, some tests may help provide information on how well a specific treatment may work for an individual. Aetna considers genotyping for CYP2C9 to inform genotype-guided dosing of coumarin derivatives experimental and investigational. Aetna considers testing to

3 detect PD-L1 expression (e.g., Ventana PD- L1 (SP263) Assay) medically necessary for persons with urothelial carcinoma who are being considered for treatment with durvalumab (Imfinzi). CPB Inflammatory Bowel Disease: Serologic Markers and Pharmacogenomic and Metabolic Assessment of Thiopurine Therapy,. Aetna considers genetic testing for the rs allele experimental and investigational for selecting persons for chronic aspirin therapy or other indications established. Sulfonylureas (e.g., amitri Aetna considers measurement of thromboxane metabolites in urine (e.g., AspirinWorks) to evaluate aspirin resistance experimental and investigational established. Aetna considers one genotyping for CYP2D6 polymorphisms medically necessary for persons with Gaucher disease type 1 who are being considered for treatment with eliglustat (Cerdelga). Repeat CYP2D6 genotyping has no proven value. Aetna considers multi-gene pharmacogenetics panels (i.e., diagnostic tests to identify specific genetic variations that may be linked to reduced/enhanced metabolism and/or severe side effects of multiple classes of drugs) experimental and investigational because the clinical value of this type of genetic testing has not been established. These tests include, but are not limited to the following: Genecept Assay, GeneSightRx, GeneSight ADHD, GeneSight Analgesic, GeneSight MTHFR and GeneSight Psychotropic testing, Millennium PGT, PersonaGene Genetic Panels, Proove Profiles, rxseek Epilepsy Drug Metabolism, OneOme RightMed Pharmacogenomic Test, INFINITI Neural Response Panel, and IDgenetix. in persons with thyroid carcinoma who are being considered for treatment with dabrafenib (Tafinlar) or vemurafenib (Zelboraf). Aetna considers testing to detect an epidermal

4 growth factor receptor (EGFR) T790 mutation (e.g., cobas EGFR Mutation Test v2) medically necessary for persons with non-small cell lung cancer being considered for treatment with osimertinib (Tagrisso). Aetna considers one genotyping for CYP2D6 polymorphisms medically necessary for persons who have been prescribed doses of tetrabenazine (Xenazine) greater than 50 mg per day. Repeat CYP2D6 genotyping has no proven value. Aetna considers genotyping for A1555G before prescribing aminoglycosides experimental and investigational. Z codes represent reasons for encounters. A corresponding procedure code must accompany a Z code if a procedure is performed. Categories Z00-Z99 are provided for occasions when circumstances other than a disease, injury or external cause classifiable to categories A00 -Y89 are recorded as 'diagnoses' or 'problems'. This can arise in two main ways: (a) When a person who may or may not be sick encounters the health services for some specific purpose, such as to receive limited care or service for a current condition, to donate an organ or tissue, to receive prophylactic vaccination (immunization), or to discuss a problem which is in itself not a disease or injury. (b) When some circumstance or problem is present which influences the person's health status but is not in itself a current illness or injury. Z Long term (current) use of other agents affecting estrogen receptors and estrogen levels. Z80.1 Family history of malignant neoplasm of trachea, bronchus and lung. Z Long term (current) use of selective estrogen receptor modulators (SERMs). Long term (current) use of methadone for pain management. long term (current) drug use for prophylactic purposes. Z79.81 Long term (current) use of agents affecting estrogen receptors and estrogen levels. Z80.41 Family history of malignant neoplasm of ovary. drug abuse and

5 dependence ( F11 - F19 ) drug use complicating pregnancy, TEENbirth, and the puerperium ( O ) long term (current) use of oral antidiabetic drugs ( Z79.84 ) long term (current) use of oral hypoglycemic drugs ( Z79.84 ) (effective 10/1/2015): New code (first year of non-draft ICD-10-CM). Factors influencing health status and contact with health services. Z80.0 Family history of malignant neoplasm of digestive organs. POA Help "Present On Admission" is defined as present at the time the order for inpatient admission occurs conditions that develop during an outpatient encounter, including emergency department, observation, or outpatient surgery, are considered POA. ) use of methodone for treatment of heroin addiction ( ICD-10-CM Diagnosis Code F11.2. Type 1 Excludes Help A type 1 excludes note is a pure excludes. It means "not coded here". A type 1 excludes note indicates that the code excluded should never be used at the same time as Z A type 1 excludes note is for used for when two conditions cannot occur together, such as a congenital form versus an acquired form of the same condition. Z80.43 Family history of malignant neoplasm of testis. Z79.84 Long term (current) use of oral hypoglycemic drugs. Persons with potential health hazards related to family and personal history and certain conditions influencing health status. The following code(s) above Z contain annotation back-references. ICD-10-CM Z is grouped within Diagnostic Related Group(s) (MS-DRG v 36.0): The 2019 edition of ICD-10-CM Z became effective on October 1, counseling practice." Mental filtering may be displayed in some clinicians who. of "internalizing" factors (anxiety, depression, and somatic symptoms) and. disorders that occur in adolescence and young adulthood (depressive, bipolar,. Antiviral therapy in chronic hepatitis B viral infection during

6 pregnancy: A systematic review and metaanalysis [Website View] [ Download PDF ]. material will equip clinicians with a basic understanding of the DSM-5 so as to. limitations to the categorical approach (APA, 2000, pp. xxxi-xxxii) and the. DSM-5, it is not sufficient to simply check off the symptoms in the diagnostic. began critical discussion and extensive consumption of the scientific. Three systematic reviews that were commissioned to support the guideline were published in January 2016:. instead of counseling to achieve mental health. I will no longer have a purpose. assessment (APA, 2013 pp ), in which the DSM-5 combines the first three. use by trained clinicians in a wide diversity of contexts and facilitates a. AASLD commissions and provides financial support for the formulation and production of Practice Guidelines / Guidances by volunteer experts. Financial support from commercial entities or the pharmaceutical industry is not accepted for the development of AASLD practice guidelines or guidances. Diagnosis and Management of Hemochromatosis: 2011 Practice Guideline by the American Association for the Study of Liver Diseases. Explain the conceptual and practical changes between the DSM-IV-TR and the DSM-5. work groups did not include clinicians, so I do not need to use this book in my. began in 1999 with pre-planning white papers that addressed a research agenda. and Statistical Manual of Mental Disorders (DSM-5; APA, 2013) continues a. Long- Term Management of the Successful Adult Liver Transplant: 2012 Practice Guideline by AASLD and the AST (Enhanced Navigation. Corrections to the AASLD Position Paper: The Management of Acute Liver Failure: Update 2011 William M. Lee, MD,1 Anne M. Larson, Apply the DSM-5 changes in your clinical work to enhance assessment, diagnostic, and. such, and to align with the World Health Organization's (WHO) International.

7